Marcus Larsson is a specialist in pediatrics, PhD in clinical physiology and one of the founders of Amniotics. He is also one of the inventors of Amniotics’ patented technology to extract neonatal Mesenchymal Stem Cells (MSC) for the treatment of serious disease states. Marcus Larsson has been a member of the Company’s board of directors since the beginning and will remain as a board member in addition to his role as CEO.
 
Amniotics is now entering a new phase where the Company’s stem cell product PulmoStem will, among other things, be evaluated in a clinical study for the treatment of Covid-19 and acute lung disease. The clinical study is conducted in Sweden and the UK.
 
In connection with Marcus Larsson’s appointment as new CEO, Kåre Engkilde leaves his current position as the Company’s CEO. Kåre will be at the Company’s disposal during a transition period.
 
"I want to thank Kåre for the significant efforts he has contributed during his time as Amniotics’ CEO. Kåre has led the preparations before and the execution of the listing of Amniotics on Nasdaq First North Growth Market and the development of the Company’s own GMP manufacturing facility in Lund," says Peter Buhl Jensen, Amniotics, chairman of the board of directors. "As Amniotics now enters a new phase of clinical trials and collaborations around the Company’s patented stem cell technologies, I would at the same time like to welcome Marcus Larsson as the new CEO of Amniotics. With his knowledge and experience in Amniotics’ key areas, Marcus will be an important addition to the Company’s continued development and success."

For more information please contact:
Peter Buhl Jensen, phone +45 2160 8922 and pbj@buhloncology.com
 

About Amniotics
 
Amniotics is a biopharma company focusing on mesenchymal stem cells (MSC) from amniotic fluid. The company was born out of the discovery of a novel source of stem cells in full-term amniotic fluid. Based on a decade of research at the internationally recognized Lund University Stem Cell Centre and the Skåne University Hospital of Lund, the company is pioneering the harvesting and propagation of tissue specific neonatal quality mesenchymal stem cells (MSC). These stem cells have unique properties for applications in regenerative medicine. Amniotics has also an, by Läkemedelsverket (Swedish MPA), approved Good Manufacturing Practice (GMP) facility to produce Advanced Therapy Medicinal Products (ATMPs). With the GMP facilities operational since 2020, Amniotics is now moving into clinical trials with the leading drug candidate, PulmoStem™ and is looking to establish strategic partnerships with researchers and companies that are interested in developing stem-cell-based therapies targeting diseases with high unmet needs.
 
Amniotics Certified Adviser on First North is Redeye AB, certifiedadviser@redeye.se, telephone: +46 (0) 8 121 576 90.
 
Learn more at www.amniotics.com.